Treat-to-target in Inflammatory Bowel Disease

Opinion
Video

Medical experts in inflammatory bowel disease (IBD) define the concept of "treat-to-target" within the context of IBD and provide current recommendations on treatment targets for ulcerative colitis and Crohn's disease, the two main forms of IBD.

  1. What does treat-to-target (t2t) mean in IBD?
    1. Is t2t the starting point for disease modification?
  2. What are the recommended treatment targets for IBD? How do they vary between UC and CD?
Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
1 KOL is featured in this Insights series.
Related Content
Arthritis Disease Severity Peaks in Spring and Fall, According to PROs

Arthritis Disease Severity Peaks in Spring and Fall, According to PROs

Lana Pine
July 25th 2024
Article
Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Abigail Brooks, MA
July 18th 2024
Podcast
| Image Credit: California Retina Consultants

Sozinibercept Combination Therapy Exhibits Durability for nAMD, DME

Connor Iapoce
July 25th 2024
Article
John Buse, MD, PhD | Credit: UNC School of Medicine

Diabetes Dialogue: CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
July 15th 2024
Podcast
FDA logo black and white | Credit: US Food and Drug Administration

FDA Approves Label Expansion for Maralixibat (Livmarli) in PFIC

Abigail Brooks, MA
July 25th 2024
Article
Lebrikizumab Shown to Have Comparable Efficacy to Dupilumab for Eczema

Lebrikizumab Shown to Have Comparable Efficacy to Dupilumab for Eczema

Tim Smith
July 25th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.